ClinicalTrials.gov
ClinicalTrials.gov Menu

Flupenthixol Decanoate in Methamphetamine Smoking - 1

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00000241
Recruitment Status : Completed
First Posted : September 21, 1999
Last Update Posted : January 12, 2017
Sponsor:
Collaborator:
Friends Research Institute, Inc.
Information provided by:
National Institute on Drug Abuse (NIDA)

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of flupenthixol decanoate for treatment of methamphetamine dependence. Also, study will compare flupenthixol with desipramine in blocking methamphetamine self-administration.

Condition or disease Intervention/treatment Phase
Substance-Related Disorders Drug: Flupenthixol Phase 2

Study Type : Interventional  (Clinical Trial)
Enrollment : 58 participants
Primary Purpose: Treatment
Official Title: Flupenthixol Decanoate in Methamphetamine Smoking
Study Start Date : February 1994
Study Completion Date : May 1996

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Methamphetamine use


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   22 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000241


Locations
United States, California
Friends Research Institute
Los Angeles, California, United States, 90025
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Friends Research Institute, Inc.
Investigators
Principal Investigator: Frank Gawin, M.D. Friends Research Institute, Inc.

ClinicalTrials.gov Identifier: NCT00000241     History of Changes
Other Study ID Numbers: NIDA-07200-1
R01-07200-1
First Posted: September 21, 1999    Key Record Dates
Last Update Posted: January 12, 2017
Last Verified: October 2016

Keywords provided by National Institute on Drug Abuse (NIDA):
methamphetamine dependence

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Methamphetamine
Flupenthixol
Flupenthixol decanoate
Decanoic acid
Central Nervous System Stimulants
Physiological Effects of Drugs
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors
Antifungal Agents
Anti-Infective Agents
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists